NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
CC E-195-2008-0-US-03 System And Method For Prostate Cancer Detection And Distribution Mapping US National Stage 12/993,854 8447384 Issued PDF
CC E-195-2008-0-FR-09 System for performing biopsies FR EP 09766260.5 Issued
CC E-195-2008-0-DE-07 System for performing biopsies DE EP 09766260.5 Issued
CC E-195-2008-0-TR-11 System for performing biopsies TR EP 09766260.5 Issued
CC E-195-2008-0-EP-06 System for performing biopsies EP National Stage 09766260.5 Issued
NIAID E-203-2008-0-PCT-02 T-Cell Enumeration Assay Using Dried Blood Spots For Diagnosis Of HIV Disease Stage PCT PCT PCT/US2009/003532 Expired
CC E-195-2008-0-PCT-02 System And Method For Prostate Cancer Detection And Distribution Mapping PCT PCT PCT/IB2009/052519 Expired
NIDDK E-235-2008-0-PCT-03 P2Y1 RECEPTOR ANTAGONISTS PCT PCT PCT/US2009/47204 Abandoned
NCI E-256-2006-0-CN-05 Self-assembling Nanoparticles Composed Of Transmembrane Peptides And Their Application For Specific Intra-tumor Delivery Of Anti-cancer Drugs CN National Stage 200780045937.9 Abandoned
NIDCR E-300-2008-0-US-01 Identification Of DSG3 As A Biomarker For The Detection Of Metastasis In Lymph Nodes US 61/186,582 Abandoned
NIAID E-280-2001-0-AU-08 Recovery of Recombinant Human Parainfluenza Virus Type 1 (HPIV1) from cDNA AU DIV 2009202359 Abandoned
NCI E-209-2008-0-JP-07 Use of MIR-26 Family As Predictive Markers Of Hepatocellular Carcinoma And Responsiveness To Therapy JP National Stage 2011-513679 Abandoned
NCI E-209-2008-0-CN-05 Use of MIR-26 Family As Predictive Markers Of Hepatocellular Carcinoma And Responsiveness To Therapy CN National Stage 200980126520.4 Abandoned
NCI E-209-2008-0-AU-04 MicroRNAS As Predictors For Hepatocellular Carcinoma With Poor Outcomes And Responses To Interferon Therapy AU National Stage 2009257410 Abandoned
NCI E-209-2008-0-EP-06 USE OF MIR-26 FAMILY AS A PREDICTIVE MARKER OF HEPATOCELLULAR CARCINOMA AND RESPONSIVENESS TO THERAPY EP National Stage 09763590.8 Abandoned
NCI E-209-2008-0-ES-10 USE OF MIR-26 FAMILY AS A PREDICTIVE MARKER OF HEPATOCELLULAR CARCINOMA AND RESPONSIVENESS TO THERAPY ES EP 09763590.8 Abandoned
NCI E-209-2008-0-GB-14 USE OF MIR-26 FAMILY AS A PREDICTIVE MARKER OF HEPATOCELLULAR CARCINOMA AND RESPONSIVENESS TO THERAPY GB EP 09763590.8 Abandoned
NCI E-209-2008-0-CH-12 USE OF MIR-26 FAMILY AS A PREDICTIVE MARKER OF HEPATOCELLULAR CARCINOMA AND RESPONSIVENESS TO THERAPY CH EP 09763590.8 Abandoned
NCI E-209-2008-0-FR-13 USE OF MIR-26 FAMILY AS A PREDICTIVE MARKER OF HEPATOCELLULAR CARCINOMA AND RESPONSIVENESS TO THERAPY FR EP 09763590.8 Abandoned
NCI E-209-2008-0-DE-09 USE OF MIR-26 FAMILY AS A PREDICTIVE MARKER OF HEPATOCELLULAR CARCINOMA AND RESPONSIVENESS TO THERAPY DE EP 09763590.8 Abandoned
NCI E-209-2008-0-IT-15 USE OF MIR-26 FAMILY AS A PREDICTIVE MARKER OF HEPATOCELLULAR CARCINOMA AND RESPONSIVENESS TO THERAPY IT EP 09763590.8 Abandoned
NCI E-209-2008-0-PCT-02 MicroRNAS As Predictors For Hepatocellular Carcinoma With Poor Outcomes And Responses To Interferon Therapy PCT PCT PCT/US2009/046999 Expired
NCI E-209-2008-0-CA-03 MicroRNAS As Predictors For Hepatocellular Carcinoma With Poor Outcomes And Responses To Interferon Therapy CA National Stage 2727633 Abandoned
NIAID E-224-2009-0-US-01 GARP (LRRC32) is Essential for the Surface Expression of Latent TGF-B US 61/185,933 Abandoned
NIDA E-027-2010-0-US-01 Useof A Small Peptide DADLE In Treating Stroke US 61/185,853 Abandoned
NIDDK E-226-2009-0-US-01 STAMP Affects The Growth Of Transformed And Ovarian Cancer Cell US 61/185,503 Abandoned
NCI E-093-2009-0-US-01 Polyphenol, Beta-Lactam, and Porphyrin Compounds as Inhibitors of TDP1 and Methods of Treating Disorders US 61/268,130 Abandoned
NCI E-256-2008-0-CA-03 SURVIVAL PREDICTOR FOR DIFFUSE LARGE B CELL LYMPHOMA CA National Stage 2726811 Issued
NCI E-256-2008-0-ES-09 Survival Predictor For Diffuse Large B Cell Lymphoma ES EP 09759517.7 Issued
NCI E-256-2008-0-IT-12 Survival Predictor For Diffuse Large B Cell Lymphoma IT EP 09759517.7 Issued
NCI E-256-2008-0-DE-08 Survival Predictor For Diffuse Large B Cell Lymphoma DE EP 09759517.7 Issued
NCI E-256-2008-0-FR-10 Survival Predictor For Diffuse Large B Cell Lymphoma FR EP 09759517.7 Issued
NCI E-256-2008-0-EP-04 Survival Predictor For Diffuse Large B Cell Lymphoma EP National Stage 09759517.7 Issued
NCI E-256-2008-0-GB-11 Survival Predictor For Diffuse Large B Cell Lymphoma GB EP 09759517.7 Issued
NCI E-321-2006-0-US-03 Regulation Of Skin Characteristics By Dickkopf 1 (DKK1) US National Stage 12/518,052 8198244 Abandoned PDF
NCI E-062-1996-0-US-12 PROSTATE SPECIFIC ANTIGEN OLIGO-EPITOPE PEPTIDE US CON 12/479,292 7871986 Expired PDF
NCI E-256-2008-0-PCT-02 A Gene Expression-based Survival Predictor For Diffuse Large B Cell Lymphoma Treated With Chemotherapy Plus Rituximab PCT PCT PCT/US2009/046421 Expired
NCI E-256-2008-0-EP-07 Survival Predictor For Diffuse Large B Cell Lymphoma EP DIV 15180558.7 Abandoned
CC E-228-2009-0-US-01 System And Method Of Integrated Biopsy And Therapy US 61/184,322 Abandoned
NCI E-194-2008-0-PCT-02 Immunotoxins and Uses Thereof PCT PCT PCT/US09/46292 Expired
NCI E-226-2006-0-US-03 METHOD OF PREPARING MACROMOLECULAR CONTRAST AGENTS AND USES THEREOF US National Stage 12/513,813 8288530 Issued PDF
NIAID E-173-2004-1-US-10 Method of Using Adenoviral Vectors to Induce an Immune Response US CON 12/477,712 Abandoned
NIAID E-326-2006-1-US-03 Codon Modified Immunogenic Compositions and Methods of Use US National Stage 12/517,194 8772256 Issued PDF
NCI E-259-2008-0-PCT-02 A Method For Identifying Patients At Risk For Developing Her-2+ Breast Cancer Brain Metastases, Based On Molecular Characteristics Of The Formalin Fixed, Paraffin Embedded (FFPE) Primary Tumor PCT PCT PCT/US09/003330 Expired
NCI E-157-2009-0-US-01 The Discovery And Validation Of MDR1-inverse Agents US 61/182,511 Abandoned
NIAID E-110-2006-0-US-03 Use Of Muramyl Dipeptide (MDP) For Treating Inflammation US National Stage 12/516,633 8603978 Issued PDF
NCI E-013-2002-0-US-07 Nucleic Acids Encoding Humanized Anti-Tag 72 CC49 Antibodies US DIV 12/474,221 7919607 Abandoned PDF
NIAID E-078-2009-0-US-01 Development Of Antigenic Chimeric Tick-borne Encephalitis Virus/dengue Virus Type 4 Recombinant Viruses (TBEV/DEN4) As Vaccine Candidates For The Prevention Of Disease Caused By TBEV US 61/181,982 Abandoned
NCI E-178-2009-0-US-01 A Dual Function Protein, ATIA, Is A Novel Diagnostic Marker For Human Glioblastoma And A Potential Therapeutic Target For Treating The Disease US 61/182,072 Abandoned
NIAID E-218-2008-0-US-02 METHOD FOR IDENTIFICATION OF T-LYMPHOCYTE ANTIGENS US ORD 12/473,096 Abandoned